Review



pher3 (y 1289) antibody  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc pher3 (y 1289) antibody
    Biomarkers analysed by IHC.
    Pher3 (Y 1289) Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pher3+(y+1289)+antibody/anti+pher3/pmc07517995-23-0-5
    Average 90 stars, based on 1 article reviews
    pher3 (y 1289) antibody - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Clinicopathologic significance of nuclear HER4 and phospho-YAP(S 127 ) in human breast cancers and matching brain metastases"

    Article Title: Clinicopathologic significance of nuclear HER4 and phospho-YAP(S 127 ) in human breast cancers and matching brain metastases

    Journal: Therapeutic Advances in Medical Oncology

    doi: 10.1177/1758835920946259

    Biomarkers analysed by IHC.
    Figure Legend Snippet: Biomarkers analysed by IHC.

    Techniques Used: Staining, Membrane

    Antibodies and conditions used for IHC analysis.
    Figure Legend Snippet: Antibodies and conditions used for IHC analysis.

    Techniques Used: Incubation

    Expression and activation of HER4 in brain-metastatic breast cancers and brain metastases. (A) Chi-square analysis of cyto.HER4, nu.4ICD and m.pHER4 in major breast cancer subtypes. * p < 0.05; *** p < 0.001; **** p < 0.0001. (B) Changes in cyto.HER4, nu.4ICD and m.pHER4 in individual matched cases, separated according to major breast cancer subtypes. Chi-square p -values indicate significant differences before and after metastasis to the brain. (C) Tile plot showing overall numbers of br.MBC and BrM co-expressing pHER receptors (columns are individual tumours). (D) Representative IHC analysis of samples from a patient whose HER2+ breast cancer recurred in the brain 7 years after diagnosis and treatment with HER2-targeted therapy. This case exemplifies concomitant induction of pHER2, pHER3 and pHER4. BrM, brain metastases; br.MBC, brain metastatic breast cancers; cyto.HER4, cytoplasmic HER4; HER4, human epidermal growth factor receptor-4; IC-NST, invasive carcinoma, no special type; IHC, immunohistochemistry; LumA/B, luminal A/B; m.pHER4, membrane-pHER4; nu.4ICD, nuclear HER4-ICD.
    Figure Legend Snippet: Expression and activation of HER4 in brain-metastatic breast cancers and brain metastases. (A) Chi-square analysis of cyto.HER4, nu.4ICD and m.pHER4 in major breast cancer subtypes. * p < 0.05; *** p < 0.001; **** p < 0.0001. (B) Changes in cyto.HER4, nu.4ICD and m.pHER4 in individual matched cases, separated according to major breast cancer subtypes. Chi-square p -values indicate significant differences before and after metastasis to the brain. (C) Tile plot showing overall numbers of br.MBC and BrM co-expressing pHER receptors (columns are individual tumours). (D) Representative IHC analysis of samples from a patient whose HER2+ breast cancer recurred in the brain 7 years after diagnosis and treatment with HER2-targeted therapy. This case exemplifies concomitant induction of pHER2, pHER3 and pHER4. BrM, brain metastases; br.MBC, brain metastatic breast cancers; cyto.HER4, cytoplasmic HER4; HER4, human epidermal growth factor receptor-4; IC-NST, invasive carcinoma, no special type; IHC, immunohistochemistry; LumA/B, luminal A/B; m.pHER4, membrane-pHER4; nu.4ICD, nuclear HER4-ICD.

    Techniques Used: Expressing, Activation Assay, Biomarker Discovery, Immunohistochemistry, Membrane

    Related Articles

    other:

    Article Title: Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling
    Article Snippet: The anti-pH3, anti-p(Y 15 ) CDK1, anti-pRpb1, anti-pRb (S 780 ) and anti-pRb (S 807/811 ), pHER2 (Y 1221/1222 ), pHER3 (Y 1289 ), and AKT antibodies were from Cell Signaling Technologies (Beverly, MA, USA).



    Similar Products

    pher3 (y 1289) antibody  (Cell Signaling Technology Inc)
    90
    Cell Signaling Technology Inc pher3 (y 1289) antibody
    Biomarkers analysed by IHC.
    Pher3 (Y 1289) Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pher3+(y+1289)+antibody/anti+pher3/pmc07517995-23-0-5
    Average 90 stars, based on 1 article reviews
    pher3 (y 1289) antibody - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Biomarkers analysed by IHC.

    Journal: Therapeutic Advances in Medical Oncology

    Article Title: Clinicopathologic significance of nuclear HER4 and phospho-YAP(S 127 ) in human breast cancers and matching brain metastases

    doi: 10.1177/1758835920946259

    Figure Lengend Snippet: Biomarkers analysed by IHC.

    Article Snippet: pHER3 (Y 1289 ) , Cell signaling , 21D3 , Rabbit , EDTA pH 8.8 , 1/50 , 1 h.

    Techniques: Staining, Membrane

    Antibodies and conditions used for IHC analysis.

    Journal: Therapeutic Advances in Medical Oncology

    Article Title: Clinicopathologic significance of nuclear HER4 and phospho-YAP(S 127 ) in human breast cancers and matching brain metastases

    doi: 10.1177/1758835920946259

    Figure Lengend Snippet: Antibodies and conditions used for IHC analysis.

    Article Snippet: pHER3 (Y 1289 ) , Cell signaling , 21D3 , Rabbit , EDTA pH 8.8 , 1/50 , 1 h.

    Techniques: Incubation

    Expression and activation of HER4 in brain-metastatic breast cancers and brain metastases. (A) Chi-square analysis of cyto.HER4, nu.4ICD and m.pHER4 in major breast cancer subtypes. * p < 0.05; *** p < 0.001; **** p < 0.0001. (B) Changes in cyto.HER4, nu.4ICD and m.pHER4 in individual matched cases, separated according to major breast cancer subtypes. Chi-square p -values indicate significant differences before and after metastasis to the brain. (C) Tile plot showing overall numbers of br.MBC and BrM co-expressing pHER receptors (columns are individual tumours). (D) Representative IHC analysis of samples from a patient whose HER2+ breast cancer recurred in the brain 7 years after diagnosis and treatment with HER2-targeted therapy. This case exemplifies concomitant induction of pHER2, pHER3 and pHER4. BrM, brain metastases; br.MBC, brain metastatic breast cancers; cyto.HER4, cytoplasmic HER4; HER4, human epidermal growth factor receptor-4; IC-NST, invasive carcinoma, no special type; IHC, immunohistochemistry; LumA/B, luminal A/B; m.pHER4, membrane-pHER4; nu.4ICD, nuclear HER4-ICD.

    Journal: Therapeutic Advances in Medical Oncology

    Article Title: Clinicopathologic significance of nuclear HER4 and phospho-YAP(S 127 ) in human breast cancers and matching brain metastases

    doi: 10.1177/1758835920946259

    Figure Lengend Snippet: Expression and activation of HER4 in brain-metastatic breast cancers and brain metastases. (A) Chi-square analysis of cyto.HER4, nu.4ICD and m.pHER4 in major breast cancer subtypes. * p < 0.05; *** p < 0.001; **** p < 0.0001. (B) Changes in cyto.HER4, nu.4ICD and m.pHER4 in individual matched cases, separated according to major breast cancer subtypes. Chi-square p -values indicate significant differences before and after metastasis to the brain. (C) Tile plot showing overall numbers of br.MBC and BrM co-expressing pHER receptors (columns are individual tumours). (D) Representative IHC analysis of samples from a patient whose HER2+ breast cancer recurred in the brain 7 years after diagnosis and treatment with HER2-targeted therapy. This case exemplifies concomitant induction of pHER2, pHER3 and pHER4. BrM, brain metastases; br.MBC, brain metastatic breast cancers; cyto.HER4, cytoplasmic HER4; HER4, human epidermal growth factor receptor-4; IC-NST, invasive carcinoma, no special type; IHC, immunohistochemistry; LumA/B, luminal A/B; m.pHER4, membrane-pHER4; nu.4ICD, nuclear HER4-ICD.

    Article Snippet: pHER3 (Y 1289 ) , Cell signaling , 21D3 , Rabbit , EDTA pH 8.8 , 1/50 , 1 h.

    Techniques: Expressing, Activation Assay, Biomarker Discovery, Immunohistochemistry, Membrane